- Home
- NUVL vs ITRI Comparison
NUVL vs ITRI Comparison
Compare NUVL & ITRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- ITRI
- Stock Information
- Founded
- NUVL 2017
- ITRI 1977
- Country
- NUVL United States
- ITRI United States
- Employees
- NUVL N/A
- ITRI N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- ITRI Electrical Products
- Sector
- NUVL Health Care
- ITRI Industrials
- Exchange
- NUVL Nasdaq
- ITRI Nasdaq
- Market Cap
- NUVL 5.8B
- ITRI 6.2B
- IPO Year
- NUVL 2021
- ITRI 1993
- Fundamental
- Price
- NUVL $78.64
- ITRI $117.91
- Analyst Decision
- NUVL Strong Buy
- ITRI Strong Buy
- Analyst Count
- NUVL 11
- ITRI 9
- Target Price
- NUVL $120.91
- ITRI $137.00
- AVG Volume (30 Days)
- NUVL 390.3K
- ITRI 600.6K
- Earning Date
- NUVL 11-11-2025
- ITRI 10-30-2025
- Dividend Yield
- NUVL N/A
- ITRI N/A
- EPS Growth
- NUVL N/A
- ITRI 44.31
- EPS
- NUVL N/A
- ITRI 5.85
- Revenue
- NUVL N/A
- ITRI $2,442,238,000.00
- Revenue This Year
- NUVL N/A
- ITRI N/A
- Revenue Next Year
- NUVL N/A
- ITRI $5.52
- P/E Ratio
- NUVL N/A
- ITRI $20.12
- Revenue Growth
- NUVL N/A
- ITRI 3.90
- 52 Week Low
- NUVL $55.54
- ITRI $90.11
- 52 Week High
- NUVL $110.00
- ITRI $140.04
- Technical
- Relative Strength Index (RSI)
- NUVL 51.21
- ITRI 36.17
- Support Level
- NUVL $77.88
- ITRI $117.51
- Resistance Level
- NUVL $83.09
- ITRI $121.09
- Average True Range (ATR)
- NUVL 3.14
- ITRI 2.41
- MACD
- NUVL 0.14
- ITRI -0.10
- Stochastic Oscillator
- NUVL 48.79
- ITRI 10.34
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About ITRI Itron Inc.
Itron Inc provides solutions that measure, manage, and analyze energy and water use. It operates under the Itron brand and manages and reports under three operating segments: Device Solutions, Networked Solutions, and Outcomes. The Device Solutions segment includes hardware products used for measurement, control, or sense that do not have communications capability embedded for use with broader Itron systems. The Networked Solutions segment includes a combination of communicating devices, network infrastructure, and associated application software designed and sold as a complete solution. The Outcome segment includes their value-added, enhanced software and services which manage, organize, analyze, and interpret data to improve decision-making and maximize operational profitability.